Skip to content
value.today

MBQ Pharma Inc.

Total raised
$2 M
1 round on record
Latest round
$2 M
Jun 2018
First round on record
Jun 2018
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of MBQ Pharma Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2018$2 MNo. 1Under $2 million

MBQ Pharma Inc.: Raise no. 1, Jun 2018

Investors in this round

8 investors had bought by the notice of Aug 14, 2026: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Puerto Rico

People named in the notice

  • Carlos A Dominguez · Executive Officer · Chief Financial Officer
  • Cornelis F Vlaar · Executive Officer, Director · Chief Development Officer
  • Eliud F Hernandez · Executive Officer · Chief Operating Officer
  • Federico F Goodsaid · Executive Officer, Director · Chief Executive Officer
  • Jose F Rodriguez-Orengo · Executive Officer · Chief Business Officer
  • Suranganie F Dharmawardhane · Executive Officer, Director · Chief Scientific Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Carlos A Dominguez, Cfo. Source: SEC Form D, newest notice filed Aug 14, 2026. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • MBQ Pharma Inc. had no revenue when it filed its newest notice of a funding round (Aug 2026).

    SEC Form D (revenue range) · Aug 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2026

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of MBQ Pharma Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 8 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by MBQ Pharma Inc.
NameRoleNamed in
Carlos A DominguezChief Financial OfficerAug 2026
Cornelis F VlaarChief Development OfficerAug 2026
Eliud F HernandezChief Operating OfficerAug 2026
Federico F GoodsaidChief Executive OfficerAug 2026
Jose F Rodriguez-OrengoChief Business OfficerAug 2026
Suranganie F DharmawardhaneChief Scientific OfficerAug 2026
Cornelis F VlaarChief Development OfficerAug 2026
Federico F GoodsaidChief Executive OfficerAug 2026
Suranganie F DharmawardhaneChief Scientific OfficerAug 2026